Cargando…
Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial
OBJECTIVES: To evaluate the morphine-sparing effects of the sequential treatment versus placebo in subjects undergoing total knee arthroplasty (TKA), the effects on pain relief, inflammation control and functional rehabilitation after TKA and safety. DESIGN: Double-blind, pragmatic, randomised, plac...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955469/ https://www.ncbi.nlm.nih.gov/pubmed/31924632 http://dx.doi.org/10.1136/bmjopen-2019-030501 |
_version_ | 1783486935580278784 |
---|---|
author | Zhuang, Qianyu Tao, Liyuan Lin, Jin Jin, Jin Qian, Wenwei Bian, Yanyan Li, Yulong Dong, Yulei Peng, Huiming Li, Ye Fan, Yu Wang, Wei Feng, Bin Gao, Na Sun, Tiezheng Lin, Jianhao Zhang, Miaofeng Yan, Shigui Shen, Bin Pei, Fuxing Weng, Xisheng |
author_facet | Zhuang, Qianyu Tao, Liyuan Lin, Jin Jin, Jin Qian, Wenwei Bian, Yanyan Li, Yulong Dong, Yulei Peng, Huiming Li, Ye Fan, Yu Wang, Wei Feng, Bin Gao, Na Sun, Tiezheng Lin, Jianhao Zhang, Miaofeng Yan, Shigui Shen, Bin Pei, Fuxing Weng, Xisheng |
author_sort | Zhuang, Qianyu |
collection | PubMed |
description | OBJECTIVES: To evaluate the morphine-sparing effects of the sequential treatment versus placebo in subjects undergoing total knee arthroplasty (TKA), the effects on pain relief, inflammation control and functional rehabilitation after TKA and safety. DESIGN: Double-blind, pragmatic, randomised, placebo-controlled trial. SETTING: Four tertiary hospitals in China. PARTICIPANTS: 246 consecutive patients who underwent elective unilateral TKA because of osteoarthritis (OA). INTERVENTIONS: Patients were randomised 1:1 to the parecoxib/celecoxib group or the control group. The patients in the parecoxib/celecoxib group were supplied sequential treatment with intravenous parecoxib 40 mg (every 12 hours) for the first 3 days after surgery, followed by oral celecoxib 200 mg (every 12 hours) for up to 6 weeks. The patients in the control group were supplied with the corresponding placebo under the same instructions. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary endpoint was the cumulative opioid consumption at 2 weeks post operation (intention-to-treat analysis). Secondary endpoints included the Knee Society Score, patient-reported outcomes and the cumulative opioid consumption. RESULTS: The cumulative opioid consumption at 2 weeks was significantly smaller in the parecoxib/celecoxib group than in the control group (median difference, 57.31 (95% CI 34.66 to 110.33)). The parecoxib/celecoxib group achieving superior Knee Society Scores and EQ-5D scores and greater Visual Analogue Scale score reduction during 6 weeks. Interleukin 6, erythrocyte sedation rate and C-reactive protein levels were reduced at 72 hours, 2 weeks and 4 weeks and prostaglandin E2 levels were reduced at 48 hours and 72 hours in the parecoxib/celecoxib group compared with the placebo group. The occurrence of adverse events (AEs) was significantly lower in the parecoxib/celecoxib group. CONCLUSIONS: The sequential intravenous parecoxib followed by oral celecoxib regimen reduces morphine consumption, achieves better pain control and functional recovery and leads to less AEs than placebo after TKA for OA. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (ID: NCT02198924). |
format | Online Article Text |
id | pubmed-6955469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-69554692020-01-27 Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial Zhuang, Qianyu Tao, Liyuan Lin, Jin Jin, Jin Qian, Wenwei Bian, Yanyan Li, Yulong Dong, Yulei Peng, Huiming Li, Ye Fan, Yu Wang, Wei Feng, Bin Gao, Na Sun, Tiezheng Lin, Jianhao Zhang, Miaofeng Yan, Shigui Shen, Bin Pei, Fuxing Weng, Xisheng BMJ Open Surgery OBJECTIVES: To evaluate the morphine-sparing effects of the sequential treatment versus placebo in subjects undergoing total knee arthroplasty (TKA), the effects on pain relief, inflammation control and functional rehabilitation after TKA and safety. DESIGN: Double-blind, pragmatic, randomised, placebo-controlled trial. SETTING: Four tertiary hospitals in China. PARTICIPANTS: 246 consecutive patients who underwent elective unilateral TKA because of osteoarthritis (OA). INTERVENTIONS: Patients were randomised 1:1 to the parecoxib/celecoxib group or the control group. The patients in the parecoxib/celecoxib group were supplied sequential treatment with intravenous parecoxib 40 mg (every 12 hours) for the first 3 days after surgery, followed by oral celecoxib 200 mg (every 12 hours) for up to 6 weeks. The patients in the control group were supplied with the corresponding placebo under the same instructions. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary endpoint was the cumulative opioid consumption at 2 weeks post operation (intention-to-treat analysis). Secondary endpoints included the Knee Society Score, patient-reported outcomes and the cumulative opioid consumption. RESULTS: The cumulative opioid consumption at 2 weeks was significantly smaller in the parecoxib/celecoxib group than in the control group (median difference, 57.31 (95% CI 34.66 to 110.33)). The parecoxib/celecoxib group achieving superior Knee Society Scores and EQ-5D scores and greater Visual Analogue Scale score reduction during 6 weeks. Interleukin 6, erythrocyte sedation rate and C-reactive protein levels were reduced at 72 hours, 2 weeks and 4 weeks and prostaglandin E2 levels were reduced at 48 hours and 72 hours in the parecoxib/celecoxib group compared with the placebo group. The occurrence of adverse events (AEs) was significantly lower in the parecoxib/celecoxib group. CONCLUSIONS: The sequential intravenous parecoxib followed by oral celecoxib regimen reduces morphine consumption, achieves better pain control and functional recovery and leads to less AEs than placebo after TKA for OA. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (ID: NCT02198924). BMJ Publishing Group 2020-01-09 /pmc/articles/PMC6955469/ /pubmed/31924632 http://dx.doi.org/10.1136/bmjopen-2019-030501 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Surgery Zhuang, Qianyu Tao, Liyuan Lin, Jin Jin, Jin Qian, Wenwei Bian, Yanyan Li, Yulong Dong, Yulei Peng, Huiming Li, Ye Fan, Yu Wang, Wei Feng, Bin Gao, Na Sun, Tiezheng Lin, Jianhao Zhang, Miaofeng Yan, Shigui Shen, Bin Pei, Fuxing Weng, Xisheng Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title | Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title_full | Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title_fullStr | Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title_full_unstemmed | Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title_short | Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial |
title_sort | postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (pipforce): a multicentre, double-blind, randomised, placebo-controlled trial |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955469/ https://www.ncbi.nlm.nih.gov/pubmed/31924632 http://dx.doi.org/10.1136/bmjopen-2019-030501 |
work_keys_str_mv | AT zhuangqianyu postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT taoliyuan postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT linjin postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT jinjin postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT qianwenwei postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT bianyanyan postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT liyulong postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT dongyulei postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT penghuiming postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT liye postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT fanyu postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT wangwei postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT fengbin postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT gaona postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT suntiezheng postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT linjianhao postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT zhangmiaofeng postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT yanshigui postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT shenbin postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT peifuxing postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial AT wengxisheng postoperativeintravenousparecoxibsodiumfollowedbyoralcelecoxibposttotalkneearthroplastyinosteoarthritispatientspipforceamulticentredoubleblindrandomisedplacebocontrolledtrial |